Phase 2 Trial Assesses 99mTc-maraciclatide for ILD Prognosis
• A Phase 2 study, PREDICT-ILD, has commenced to evaluate 99mTc-maraciclatide, a novel molecular imaging agent, for predicting interstitial lung disease (ILD) progression.
• The study will compare 99mTc-maraciclatide uptake in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF fibrosing-ILD, against healthy controls to assess its efficacy as a prognostic marker.
• Researchers aim to determine if 99mTc-maraciclatide can identify αvβ3 activity and predict disease progression in patients with fibrosing ILD, potentially improving treatment strategies.
• The PREDICT-ILD study, involving multiple NHS sites, seeks to address the urgent need for better diagnostic tools in managing unpredictable ILD progression.
© Copyright 2025. All Rights Reserved by MedPath